Recurrent Small Cell Lung Cancer (SCLC) Completed Phase 2 Trials for Aflibercept (DB08885)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00828139S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung CancerTreatment